1
Predicted Biomarkers of CDK4/6 Inhibitors (Palbociclib) in ER-positive Metastasis Breast Cancer
Condition(s):Breast CancerLast Updated:February 28, 2020Recruiting
Palbociclib: 302 Clinical Trials, Page 1 of 31
Hide Studies Not Open or Pending
2
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
Condition(s):Triple Negative Breast Cancer; Locally Advanced Breast Cancer; Recurrent Breast Cancer; Metastatic Breast Cancer; ER+ Breast Cancer; HER2-positive Breast CancerLast Updated:May 19, 2021Recruiting
3
Palbociclib Plus Letrozole in Hormone Receptor Positive Residual Disease After Neoadjuvant Chemotherapy
Condition(s):Breast CancerLast Updated:September 13, 2021Recruiting
4
Histology-Independent Study of Palbociclib in Patients With Advanced Cancer
Condition(s):Cancer, AdvancedLast Updated:June 21, 2018Withdrawn
5
A Trial to Assess the Activity and Safety of Palbociclib in Patients With Well and Moderately Differentiated Metastatic Pancreatic Neuroendocrine Tumors (pNET)
Condition(s):Pancreatic Neuroendocrine CancerLast Updated:January 23, 2018Completed
6
Palbociclib Plus Letrozole For Postmenopausal Women With HR(+) HER2(-) Advanced Breast Cancer For Whom Letrozole Is Deemed Appropriate
Condition(s):Advanced Breast Cancer FemaleLast Updated:June 2, 2021Completed
7
Neoadjuvant Biomarker ResearcH Study of Palbociclib Combined With Endocrine Therapy in Estrogen Receptor Positive/HER2 Negative Breast CAncer (NeoRHEA)
Condition(s):Breast Cancer FemaleLast Updated:August 5, 2020Completed
8
Palbociclib Plus Letrozole Treatment After Progression to Second Line Chemotherapy for Women With ER/PR-positive Ovarian Cancer.
Condition(s):Ovarian CancerLast Updated:August 30, 2021Recruiting
9
Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer
Condition(s):Breast CancerLast Updated:March 8, 2021Active, not recruiting
10
High Risk ER+HER2- T1-2N0-1 Early Breast Cancer With Palbociclib Plus Endocrine Therapy(HIPEx)
Condition(s):Breast CancerLast Updated:April 20, 2020Recruiting